Tharimmune Förvaltning

Förvaltning kriterier kontrolleras 0/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Mark Wendland

Verkställande direktör

n/a

Total ersättning

VD-lön i procent	n/a
Anställning som VD	less than a year
Ägande av VD	n/a
Ledningens genomsnittliga anställningstid	less than a year
Styrelsens genomsnittliga mandatperiod	less than a year

Senaste uppdateringar av ledningen

Recent updates

Tharimmune And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization

Jan 23

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

VD OCH KONCERNCHEF

Mark Wendland (46 yo)

less than a year

Anställning

Mr. Mark Wendland is Chairman of the Board of Tharimmune, Inc. from February 5, 2026. Mr. Wendland is Chief Executive Officer & Director of Tharimmune, Inc. He was previously a Partner and Chief Operating...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Mark Wendland	CEO & Chairman of the Board	less than a year	inga uppgifter	inga uppgifter
Mark Toomey	President	less than a year	inga uppgifter	inga uppgifter
Jacob Asbury	Chief Financial Officer	less than a year	inga uppgifter	inga uppgifter
Angela Radkowski	Chief Operating Officer	no data	inga uppgifter	inga uppgifter

0.2yrs

Genomsnittlig anställningstid

46yo

Genomsnittlig ålder

Erfaren ledning: THAR s ledningsgrupp anses inte vara erfaren ( 0.2 års genomsnittlig anställningstid), vilket föreslår ett nytt team.

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Mark Wendland	CEO & Chairman of the Board	no data	inga uppgifter	inga uppgifter
Vaughn Smider	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Jill Sommers	Director	no data	inga uppgifter	inga uppgifter
Gary Stetz	Independent Director	less than a year	inga uppgifter	0.26% $ 454.1k
Sireesh Appajosyula	Director	4.6yrs	US$791.16k	0.16% $ 287.4k
John Lambert	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Andreas Kremer	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Alan Bonder	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Vincent LoPriore	Director	less than a year	inga uppgifter	0% $ 0
Clay Kahler	Independent Director	less than a year	inga uppgifter	0% $ 0
William Wiley	Independent Director	no data	inga uppgifter	inga uppgifter

0.8yrs

Genomsnittlig anställningstid

56.5yo

Genomsnittlig ålder

Erfaren styrelse: THAR s styrelse anses inte vara erfaren ( 0.8 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/02/16 09:08
Aktiekurs vid dagens slut	2026/02/13 00:00
Intäkter	2025/09/30
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Tharimmune, Inc. bevakas av 1 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Ashok Kumar	ThinkEquity LLC

Tharimmune Förvaltning

Förvaltning kriterier kontrolleras 0/4

Viktig information

Senaste uppdateringar av ledningen

Tharimmune, Inc. Announces Appointment of Angela Radkowski as Chief Operating Officer and Updates Board Committee Composition, Effective February 5, 2026

Tharimmune, Inc. Announces Board Appointments, Effective February 1, 2026

Less than half of directors are independent

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer, Effective December 12, 2025

High number of new directors

High number of new directors

Recent updates

Tharimmune, Inc. Announces Appointment of Angela Radkowski as Chief Operating Officer and Updates Board Committee Composition, Effective February 5, 2026

Tharimmune, Inc. Announces Board Appointments, Effective February 1, 2026

Less than half of directors are independent

Tharimmune And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization

Tharimmune, Inc. has completed a Follow-on Equity Offering in the amount of $54.8943 million.

Tharimmune Receives Non-Compliance Notice from Nasdaq

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer, Effective December 12, 2025

Tharimmune, Inc. Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Tharimmune, Inc. announced that it has received $544.997618 million in funding from a group of investors

Tharimmune, Inc. announced that it expects to receive $540 million in funding from a group of investors

Tharimmune, Inc. has filed a Follow-on Equity Offering in the amount of $5.349996 million.

New major risk - Share price stability

Tharimmune, Inc. has filed a Follow-on Equity Offering in the amount of $1.74 million.

High number of new directors

High number of new directors

Tharimmune, Inc Announces Board Changes, Effective from June 11, 2025

New major risk - Negative shareholders equity

New minor risk - Share price stability

Tharimmune, Inc. Announces Board and Committee Changes

Tharimmune, Inc., Annual General Meeting, Jun 10, 2025

Less than half of directors are independent

Tharimmune, Inc. Appoints Vincent Lopriore as Board Member

Tharimmune Receives A Non-Compliance Notice from the Listing Qualifications Staff of Nasdaq

Tharimmune, Inc. Announces Phase 2 Study Plan for TH104 in Patients with Moderate-To-Severe Pruritus Associated with Primary Biliary Cholangitis

Tharimmune, Inc. Presents Positive Clinical Data at AASLD Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune, Inc. (NasdaqCM:THAR) entered into a nonbinding, exclusive letter of intent to acquire Intract Pharma Ltd.

New major risk - Financial position

Tharimmune, Inc. Appoints David Jones to Its Scientific Advisory Board

Tharimmune, Inc. announced that it has received $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group

Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces 1-for-15 Reverse Stock Split, Intends to Bring it into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104

Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (Pbc)

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tharimmune, Inc. has filed a Follow-on Equity Offering.

Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset

New major risk - Shareholder dilution

Less than half of directors are independent

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2 HER3 Solid Tumors Via Bispecific and ADC Antibodies and Biologics

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Hillstream BioPharma, Inc. Announces Initial Results Evaluating the Synergy

Hillstream BioPharma, Inc. Announces Acceptance of Abstract At AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-Functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma, Inc. to Host Virtual R&D Day to Showcase Its Emerging Immuno-Oncology Pipeline Targeting Drug-Resistant Cancers

Hillstream BioPharma Receives Non-Compliance Written Notice from the Nasdaq

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

Hillstream BioPharma, Inc. (NasdaqCM:HILS) announces an Equity Buyback for $1 million worth of its shares.

Hillstream BioPharma, Inc. announced delayed annual 10-K filing

Hillstream BioPharma, Inc. has completed an IPO in the amount of $15 million.

No independent directors

VD OCH KONCERNCHEF

Ledningsgrupp

Styrelseledamöter

Företagsanalys och finansiella data Status

Datakällor

Analysmodell och snöflinga

Industri- och sektormått

Källor för analytiker